Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

References

• LavanchyDEvolving epidemiology of hepatitis C virusClin Microbiol Infect201117210711521091831
   PubMed Web of Science ®Google Scholar
• WylesDLMoving beyond interferon alfa: investigational drugs for hepatitis C virus infectionTop HIV Med201018413213621107012
   PubMedGoogle Scholar
• FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med20023471397598212324553
   PubMed Web of Science ®Google Scholar
• VermehrenJSarrazinCNew HCV therapies on the horizonClin Microbiol Infect201117212213421087349
   PubMed Web of Science ®Google Scholar
• ZeuzemSClinical implications of hepatitis C viral kineticsJ Hepatol199931Suppl 16164
   Web of Science ®Google Scholar
• DahlGSandstromAAkerblomEDanielsonUHResistance profiling of hepatitis C virus protease inhibitors using full-length NS3Antivir Ther200712573374017713156
   PubMed Web of Science ®Google Scholar
• FlintMMullenSDeatlyAMSelection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034)Antimicrob Agents Chemother200953240141118936191
   PubMed Web of Science ®Google Scholar
• StrahotinCSBabichMHepatitis C variability, patterns of resistance, and impact on therapyAdv Virol2012201226748322851970
   PubMedGoogle Scholar
• ContrerasAMHiasaYHeWTerellaASchmidtEVChungRTViral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication systemJ Virol200276178505851712163570
   PubMed Web of Science ®Google Scholar
• LontokEHarringtonPHoweAHepatitis C virus drug resistance-associated substitutions: state of the art summaryHepatology20156251623163226095927
   PubMed Web of Science ®Google Scholar
• LiuRCurrySMcMonaglePSusceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvirAntimicrob Agents Chemother201559116922692926303801
   PubMed Web of Science ®Google Scholar
• FornsXGordonSCZuckermanEGrazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentJ Hepatol201563356457225895428
   PubMed Web of Science ®Google Scholar
• ZeuzemSGhalibRReddyKRGrazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trialAnn Intern Med2015163111325909356
   PubMed Web of Science ®Google Scholar
• SulkowskiMSEronJJWylesDOmbitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trialJAMA2015313121223123125706092
   PubMed Web of Science ®Google Scholar
• LawitzEJDvory-SobolHDoehleBPClinical Resistance to Velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A proteinAntimicrob Agents Chemother20166095368537827353271
   PubMed Web of Science ®Google Scholar
• McPheeFHernandezDYuFResistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevirHepatology201358390291123504694
   PubMed Web of Science ®Google Scholar
• HoweAYBlackSCurrySVirologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infectionClin Infect Dis201459121657166525266289
   PubMed Web of Science ®Google Scholar
• McPheeFSheafferAKFriborgJPreclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-6,50,032)Antimicrob Agents Chemother201256105387539622869577
   PubMed Web of Science ®Google Scholar
• JensenDShermanKEHezodeCDaclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-respondersJ Hepatol2015631303725703086
   PubMed Web of Science ®Google Scholar
• Pilot-MatiasTTripathiRCohenDIn vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450Antimicrob Agents Chemother201559298899725451053
   PubMed Web of Science ®Google Scholar
• CoburnCAMeinkePTChangWDiscovery of MK-8742: an HCV NS5A inhibitor with broad genotype activityChemMedChem20138121930194024127258
   PubMed Web of Science ®Google Scholar
• ChenZWLiHRenHHuPGlobal prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataSci Rep201662031026842909
   PubMed Web of Science ®Google Scholar
• EASL recommendations on treatment of hepatitis C 2015J Hepatol201563119923625911336
   PubMed Web of Science ®Google Scholar
• AASLDHCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C2017 Available from: http://www.hcvguidelines.orgAccessed June 15, 2017
   Google Scholar
• SarrazinCLathouwersEPeetersMPrevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European regionAntiviral Res2015116101625614456
   PubMed Web of Science ®Google Scholar
• SarrazinCKiefferTLBartelsDDynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevirGastroenterology200713251767177717484874
   PubMed Web of Science ®Google Scholar
• McHutchisonJGEversonGTGordonSCTelaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infectionNew Engl J Med2009360181827183819403902
   PubMed Web of Science ®Google Scholar
• KiefferTLSarrazinCMillerJSTelaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsHepatology200746363163917680654
   PubMed Web of Science ®Google Scholar
• ZeuzemSDusheikoGMSalupereRSofosbuvir and ribavirin in HCV genotypes 2 and 3New Engl J Med2014370211993200124795201
   PubMed Web of Science ®Google Scholar
• SedeMMLauferNLQuarleriJPrevious failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patientsInt J Antimicrob Agents201546221922426100213
   PubMed Web of Science ®Google Scholar
• LawitzESulkowskiMSGhalibRSimeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomized studyLancet201438499561756176525078309
   PubMed Web of Science ®Google Scholar
• AfdhalNReddyKRNelsonDRLedipasvir and sofosbuvir for previously treated HCV genotype 1 infectionN Engl J Med2014370161483149324725238
   PubMed Web of Science ®Google Scholar
• ZeuzemSJacobsonIMBaykalTRetreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinN Engl J Med2014370171604161424720679
   PubMed Web of Science ®Google Scholar
• BeloukasAKingSChildsKDetection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UKClin Microb2015211110331039
   Web of Science ®Google Scholar